Hopp not wavering but sinking €80m into CureVac
This article was originally published in Scrip
It's not easy to raise large sums of cash for biotech drug development these days, so having software billionaire Dietmar Hopp on side is an enviable position to be in. And despite the recent blow to his portfolio dealt by the late-stage failure of Agennix's talactoferrin (scripintelligence.com, 7 August 2012), his commitment to biotech is "unwavering", according to one of the key curators of his biotech portfolio, Dr Friedrich von Bohlen. Today's announcement by CureVac would appear to demonstrate this.
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.